

## **ChromaDex to Present at the 30th Annual ROTH Conference on March 12, 2018**

IRVINE, Calif., March 06, 2018 — ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, has been invited to present at the 30<sup>th</sup> Annual ROTH Capital Partners Conference. The conference is being held on March 11-14, 2018 at The Ritz-Carlton in Dana Point, Calif.

ChromaDex management is scheduled to present on Monday, March 12<sup>th</sup> at 7:30 a.m. Pacific time, with one-on-one meetings held throughout the day.

For more information about the conference or to schedule a one-on-one meeting with ChromaDex management, please contact your ROTH representative or the Company's investor relations team at 949-574-3860.

### **About ChromaDex:**

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. To learn more about ChromaDex, please visit [www.ChromaDex.com](http://www.ChromaDex.com).

### **Forward-Looking Statements:**

This release contains forward-looking statements relating to ChromaDex and ChromaDex's business within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the results of the recently published study and whether it is further confirmation as to the benefits of NIAGEN®. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at [www.sec.gov](http://www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by

these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. Embroider

**ChromaDex Investor Relations Contact:**

Andrew Johnson, Director of Investor Relations  
949-419-0288  
andrewj@chromadex.com

**ChromaDex Public Relations Contact:**

Breah Ostendorf, Director of Marketing  
949-537-4103  
breaho@chromadex.com

